- Conditions
- Neoplasms
- Interventions
- Sunitinib, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 285
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neoplasms
- Interventions
- SU011248
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 38
- States / cities
- Aurora, Colorado • Littleton, Colorado • Orlando, Florida + 29 more
- Conditions
- Kidney Cancer
- Interventions
- erlotinib hydrochloride, sunitinib malate, biopsy
- Drug · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Portland, Oregon • Salem, Oregon
- Conditions
- Breast Cancer
- Interventions
- sunitinib alone, sunitinib plus paclitaxel, doxorubicin and cyclophosphamide
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Sunitinib, Temsirolimus, Sorafenib, Pazopanib, Everolimus, Axitinib
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Uterine Sarcoma, Uterine Leiomyosarcoma
- Interventions
- sunitinib malate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Melanoma
- Interventions
- sunitinib, nivolumab
- Drug
- Lead sponsor
- California Pacific Medical Center Research Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Intraocular Melanoma
- Interventions
- cisplatin, sunitinib malate, tamoxifen citrate, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- San Diego Pacific Oncology & Hematology Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Encinitas, California
- Conditions
- Renal Cell Cancer
- Interventions
- Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 886 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 93
- States / cities
- Daphne, Alabama • Mobile, Alabama • Beverly Hills, California + 41 more
- Conditions
- Renal Cell Carcinoma Metastatic
- Interventions
- Abemaciclib, Sunitinib
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Sunitinib, Temsirolimus
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Burlington, Vermont
- Conditions
- Renal Cell Carcinoma, Metastatic
- Interventions
- Intuvax (INN: ilixadencel), Sunitinib
- Biological · Drug
- Lead sponsor
- Mendus
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Saint Paul, Minnesota + 1 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging
- Procedure
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Neoplasms
- Interventions
- Sunitinib malate, Taxotere
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 8
- States / cities
- Berkely, California • Shreveport, Louisiana • Beaumont, Texas + 5 more
- Conditions
- Solid Tumors, Breast Cancer, Neoplasms
- Interventions
- SU011248; Capecitabine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Albuqurque, New Mexico • Nashville, Tennessee
- Conditions
- Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, Sunitinib Malate, Trebananib
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 12
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 9 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 488
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Burbank, California + 295 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 11
- States / cities
- Duarte, California • Pasadena, California • San Francisco, California + 6 more
- Conditions
- Kidney Cancer
- Interventions
- therapeutic allogeneic lymphocytes, sunitinib malate
- Biological · Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Neurofibromatosis, NF1, Plexiform Neurofibromas
- Interventions
- Sutent®/Sunitinib
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 3 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Recurrent Childhood Central Nervous System Embryonal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- sunitinib malate, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging, laboratory biomarker analysis
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 11 more
- Conditions
- Breast Neoplasms
- Interventions
- SU011248, Paclitaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 6
- States / cities
- Harvey, Illinois • Indianapolis, Indiana • Munster, Indiana + 1 more
- Conditions
- Kidney Cancer
- Interventions
- Gemcitabine, Sunitinib
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 99
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Stanford, California + 77 more
- Conditions
- Cancer
- Interventions
- Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Lynwood, California + 46 more